Thomas Waibel Joins Chromatin Bio

Dr Waibel specialises in the development of synthetic gene regulation tools. He has a strong background in transcriptional control mechanisms and has extensive experience in the biotechnology sector. He joined Chromatin Bioscience as our first employee in 2023 and has been recently promoted to Director of Platform Technology. In his previous role at Synpromics, also founded by our CEO in 2010, Thomas was key in establishing the company's frameworks and successfully led the proof of concept for their synthetic promoter technology. Throughout his career, Thomas has successfully managed cross-functional teams and contributed to high-impact projects in industrial biotechnology and gene therapy. With a strong commitment to advancing engineering biology, Thomas continues to drive technological innovations at Chromatin Bioscience.